

COVID-19 vaccines tolerated in patients with paclitaxel and docetaxel allergy

Aleena Banerji , Anna R. Wolfson, Lacey B. Robinson, Aubree E. McMahon, Amelia S. Cogan, Rebecca R. Saff, Kimberly G. Blumenthal

First published: 14 November 2021

<https://doi-org.bibliosan.clas.cineca.it/10.1111/all.15178>

Funding information:

None.

ACKNOWLEDGEMENTS:

Mass General Hospital allergy faculty and staff for evaluation and management of patients.

To the Editor,

After initial reports of anaphylaxis to the messenger RNA (mRNA) COVID-19 vaccines, the Centers for Disease Control and Prevention (CDC) put forth guidance stating that patients with a history of anaphylaxis to vaccine components like polyethylene glycol (PEG) should not receive the mRNA COVID-19 vaccines.¹ To address this clinical challenge and decrease vaccine hesitancy, we published an approach to guide COVID-19 vaccination in high-risk allergy individuals.²⁻⁴ While the etiology of anaphylaxis to mRNA COVID-19 vaccines remains unclear, PEG continues to be an important focus.^{5,6} Paclitaxel contains polyoxyl-35 castor oil—a PEG derivative and structurally similar to the excipient in Pfizer-BioNTech and Moderna COVID-19 vaccines—and docetaxel contains polysorbate 80—the excipient in Janssen COVID-19 vaccine. Given this, we sought to assess the utility of pre-vaccine excipient skin testing (ST), risk stratification, and COVID-19 vaccine tolerability in oncology patients with a history of paclitaxel or docetaxel hypersensitivity reaction (HSR).

We included consecutive paclitaxel or docetaxel HSR patients referred to Mass General Brigham allergy/immunology for evaluation prior to COVID-19 vaccination. Evaluation included clinical risk assessment and excipient ST as previously described.^{2,4} Clinical details were obtained by electronic health record (EHR) review. COVID-19 vaccine tolerance was determined by an allergy/immunology physician (AB) using EHR review, phone call, and/or e-mail. This study was approved by the Massachusetts General Brigham Institutional Review Board and deemed minimal risk.

Between December 30, 2020, and April 2, 2021, 21 patients with paclitaxel ($n = 17$) or

docetaxel ($n = 4$) HSR were referred (Table 1). Most were female ($n = 20$, 95%) and white ($n = 20$, 95%). Approximately half of HSRs occurred in the past 4 years ($n = 11$, 52%), and 14 (67%) HSRs were severe grade 3.⁷ Twenty patients (95%) had negative excipient ST. One paclitaxel HSR patient had positive ST (methyl-prednisolone acetate PEG3350, 0.4 mg/ml intradermal) and tolerated the Janssen COVID-19 vaccine (Table 2). All patients completed COVID-19 vaccination with no reaction ($n = 19$, 90%) or with mild symptoms treated with antihistamines alone ($n = 2$, 10%). Of 17 patients with history of paclitaxel HSR, 12 (71%) received an mRNA COVID-19 vaccine and none had a reaction.

TABLE 1. Characteristics of Patients with a Paclitaxel or Docetaxel Hypersensitivity Reaction Referred for Allergy Evaluation prior to COVID-19 Vaccination.

Characteristics	No. (%)		
	All ($n = 21$)	Paclitaxel allergy ($n = 17$)	Docetaxel allergy ($n = 4$)
Age, mean (SD), year	57 (10.5)	58 (10.7)	52 (8.6)
Female	20 (95)	17 (100)	3 (75)
Race			
White	20 (95)	17 (100)	3 (75)
Asian	1 (5)	0 (0)	1 (25)
History of atopy	14 (67)	12 (71)	2 (50)
Anaphylaxis	12 (57)	11 (65)	1 (25)
Allergic rhinitis	5 (24)	4 (24)	1 (25)
Food allergy	5 (24)	4 (24)	1 (25)
Asthma	4 (19)	3 (18)	1 (25)
Atopic dermatitis	1 (5)	1 (6)	0 (0)
Time since hypersensitivity reaction			
Less than 1 year	8 (38)	6 (35)	2 (50)
1–4 years	3 (14)	3 (18)	0 (0)

^a Cutaneous: hives, rash, itching, swelling (not throat), and flushing; respiratory: wheezing, chest tightness, shortness of breath, cough, and sensation of throat closing; gastrointestinal: gastrointestinal upset, abdominal cramping, diarrhea, vomiting, and nausea; cardiovascular: tachycardia and hypotension; other: 7 patients had back pain, 1 patient had lightheadedness, and 1 patient had sinus pressure.

- ^b Grading of reaction based on Ring and Messmer criteria.⁷
- ^c One patient received acetaminophen and oxycodone, and 2 patients received unknown treatment.
- ^d Twelve patients received Pfizer-BioNTech, and 4 patients received Moderna COVID-19 vaccine.
- ^e Nine patients received Pfizer-BioNTech, and 3 patients received Moderna COVID-19 vaccine.
- ^f Three patients received Pfizer-BioNTech, and 1 patient received Moderna COVID-19 vaccine.

TABLE 2. Patients with a History of Hypersensitivity Reactions to Paclitaxel or Docetaxel with Positive Skin Testing or Reaction to COVID-19 Vaccination

ID	Age	Sex	Other drug/vaccine allergy history	Reaction to paclitaxel/docetaxel				COVID-19 va
				Drug	Onset	Reaction symptoms	Reaction treatment	Excipient skin testing results ^a
1	53	F	Influenza vaccine (vision changes, wheezing, shortness of breath) Ampicillin (hives)	Paclitaxel	15 mins	Shortness of breath, chest pain, loss of consciousness	Diphenhydramine, unspecified steroid	Positive to PEG ^b
2	51	F	Influenza vaccine (facial erythema, dizziness) Pertuzumab and trastuzumab (flushing)	Docetaxel	5 mins	Flushing, diarrhea	Diphenhydramine, famotidine	Negative to PEG and polysorbate 80

Abbreviation: PEG: polyethylene glycol.

^a Skin testing protocols published previously^{2, 4}

^b Positive to methyl-prednisolone acetate intradermal 0.4 mg/ml.

This case series of 21 patients suggests that patients with paclitaxel (containing the excipient

polyoxyl-35 castor oil/PEG derivative) or docetaxel (containing the excipient polysorbate 80) HSRs tolerate COVID-19 vaccination. While 2 patients (10%) developed reactions after COVID-19 vaccination, symptoms resolved with antihistamines alone. The reactions do not appear related to the patient's specific excipient allergy history (e.g., docetaxel HSR patient developed reaction with mRNA vaccine), and in fact, no reactions occurred in paclitaxel HSR patients that received an mRNA COVID-19 vaccine. It remains unclear if the paclitaxel HSR patient with positive intradermal PEG ST would have tolerated mRNA COVID-19 vaccination, but experience to date indicates that positive PEG intradermal ST does not predict reactions to mRNA COVID-19 vaccines.⁴

CDC guidance advises patients with PEG allergy to proceed with Janssen COVID-19 vaccination while patients with polysorbate 80 allergy can proceed with mRNA COVID-19 vaccines.¹ However, if both COVID-19 vaccine platforms are not routinely accessible, allergy/immunology consultation may be useful for allergy risk assessment and vaccine guidance. Furthermore, if mRNA COVID-19 vaccines are proven optimal for oncology patients, allergy assessment and limited excipient ST (e.g., Miralax, PEG- 3350)^{2, 4} can provide reassurance prior to mRNA COVID-19 vaccination in patients with HSR to chemotherapeutics containing PEG. We continue to advise 30-minute monitoring post-COVID-19 vaccination for all patients with any history of anaphylaxis per CDC guidance.¹

This study was limited by its small sample from a single institution and retrospective study design. Additionally, the study included patients with a history of hypersensitivity to drugs (i.e., paclitaxel) that do not contain the specific form of PEG contained in the vaccines, which is a PEGylated form of PEG forming PEGylated lipids. It has been frequently reported that hypersensitivity to drugs containing PEG (in its native form) or its derivatives (and not containing the PEGylated form of PEG) is not a contraindication for receiving the COVID-19 mRNA vaccines.⁸

The role of excipient ST prior to COVID-19 vaccination appears limited.^{8, 9} Patients in our study largely tolerated COVID-19 vaccination despite paclitaxel or docetaxel HSR, and there is no identified role to date for the use of skin testing to PEG/polysorbate 80 prior to COVID-19 vaccination in these patients.⁸

CONFLICT OF INTEREST

Dr. Blumenthal receives grant support from the NIH/NIAID K01 AI12563 and the Massachusetts General Hospital Department of Medicine Transformative Scholar Program.

REFERENCES



- 1 Center for Disease Control and Prevention. *Information about COVID-19 Vaccines for People with Allergies*. Center for Disease Control and Prevention; 2021.

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/specific-groups/allergies.html>

. Accessed June 21, 2021.

[Google Scholar](#)

2 Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. *J Allergy Clin Immunol Pract.* 2021; 9(4): 1423- 1437. [10.1016/j.jaip.2020.12.047](https://doi.org/10.1016/j.jaip.2020.12.047) . Epub 2020 Dec 31.

[Crossref](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

3 Banerji A, Wolfson AR, Wickner PG, et al. COVID-19 vaccination in patients with reported allergic reactions: updated evidence and suggested approach. *J Allergy Clin Immunol Pract.* 2021; 9(6): 2135- 2138.

[Crossref](#) | [PubMed](#) | [Google Scholar](#)

4 Wolfson AR, Robinson LB, Li L, et al. First dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing. *J Allergy Clin Immunol Pract.* 2021; 9(9): 3308- 3320.e3.

[Crossref](#) | [PubMed](#) | [Google Scholar](#)

5 Sellaturay P, Nasser SM, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. *Clin Exp Allergy.* 2021; 51(6): 861- 863. [10.1111/cea.13874](https://doi.org/10.1111/cea.13874)

[Wiley Online Library](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

6 Warren CM, Snow TT, Lee AS, et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. *JAMA Netw Open.* 2021; 4(9):e2125524.

[Crossref](#) | [PubMed](#) | [Google Scholar](#)

7 Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. *Lancet.* 1977; 1(8009): 466- 469.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

8 Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. *J Allergy Clin Immunol Pract.* 2021; 9(10): 3546- 3567.

[Crossref](#) | [PubMed](#) | [Google Scholar](#)

9 Troelnikov A, Perkins G, Yuson C, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in PEG allergic patients. *J Allergy Clin Immunol.* 2021; 148(1): 91- 95.

[Crossref](#) | [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

About Wiley Online Library

Privacy Policy

Terms of Use

Cookies

Accessibility

Publishing Policies

Help & Support

Contact Us

Training and Support

DMCA & Reporting Piracy

Opportunities

Subscription Agents

Advertisers & Corporate Partners

Connect with Wiley

The Wiley Network

Wiley Press Room

Copyright © 1999-2021 John Wiley & Sons, Inc. All rights reserved